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Abstract
Aims and Objectives- The objective of this study was to assess the effect of the uro-
selective α1-blocker Tamsulosin on urodynamic parameters and quality of life in male 
patients with Type I primary bladder neck obstruction (PBNO)
Materials and methods- It is a single centre prospective observational study done in 
Department of Urology in CMC Vellore from July 2013 to December 2014. Sample size 
was calculated based on the study by Chang et al keeping alpha and beta error 5 % 
and 20% respectively. The calculated sample size was 28 patients. All male patients in 
age group between 18-50 years being diagnosed with type I PBNO (High pressure low 
flow) after Video urodynamic study were recruited in the study. All patients had 
cystoscopy to rule out urethral stricture. Patients who had  diabetes mellitus, psychiatric 
illness, neurological disease, allergy to  tamsulosin, previous pelvic surgery and those 
having absolute indication for surgical intervention(presence of obstructive nephropathy 
or uropathy) were excluded from the study. All of them were started with Tablet 
Tamsulosin 0.4 mg once at bed time for 3 months. Urodynamic study, IPSS score, 
Uroflow were repeated after 3 months and data’s collected. Primary outcome was 
defined as decrease in pdetQmax by 15%.The secondary outcomes were defined as 
increase in Qmax by 2.5 mL/s, IPSS  reduction by 25 %, improvement in Quality of life 
index, decrease in post void residual urine volume and  decrease in bladder outlet index 
below 40
Results: Total of 39 patients were included in the study. 21 patients completed the 
follow up as per protocol. Mean age group of these 21   patients was 41 years. Mean 
prostate volume was 13 cc. Relative to baseline, there was reduction in the median I-
PSS (from 22 to 12), median QOL (from 5 to 4), median post-void residual urine (from 
82ml to 50 ml), an increase in median maximum flow rate (from 8 to 10 ml) after 3 
month of treatment. 57 % achieved the primary outcome i.e. decrease in pdetQmax by 
15 % .80 % patients had more 25 % improvement in their IPPS .52% patients had A-G 
less 40 after the treatment. 47 % complained of abnormal ejaculation and 14 % 
complained of transient   giddiness.
Conclusion- Our clinical study shows statistical significant improvement of both the 
clinical and urodynamic parameters after treatment with Tab Tamsulosin– alpha 1a 
receptor blocker. It also shows that the patients who have A-G no between 40-60 before 
treatment are more likely to benefit with the alpha blockers.
                                                       
